Communiqués BioNTech SE

Actions

BNTX

US09075V1026

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 06/08/2026			Varia. 5j.	Varia. 1 janv.
91,19 ^USD	-1,07%		-1,79%	-4,21%

06/08	Les actions européennes cotées aux États-Unis sous forme d'ADR s'inscrivent en hausse lors de la séance de jeudi	MT
05/08	BIONTECH SE : Opinion positive de Berenberg Bank	ZM

Communiqués

04/08	BioNTech : Q2 2026 Finanzbericht	PU
04/08	BioNTech : BNTX Q2 2026 Exhibit 99.1 (Quarterly Report)	PU
04/08	BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update	GL
03/08	BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer	GL
29/07	European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union	GL
22/07	The UPC’s Growing Role In COVID Patent Disputes	AQ
21/07	BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026	GL
24/06	A Sovereign Bet On Science Could Save Millions of Lives	AQ
30/05	Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial	GL
22/05	BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting	GL
18/05	BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026	AQ
15/05	BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026	GL
07/05	BioNTech Announces New ADS Repurchase Program	GL
05/05	BioNTech : BNTX 1Q 2026 Presentation	PU
05/05	BioNTech : Q1 2026 Präsentation	PU
05/05	BioNTech : BNTX Q1 2026 Exhibit 99.1 (Quarterly Report)	PU
05/05	BioNTech : Q1 2026 Finanzbericht	PU
05/05	BioNTech : BNTX 4QFY 2025 Presentation FINAL 200326 v2	PU
05/05	BioNTech Announces First Quarter 2026 Financial Results and Corporate Update	GL
21/04	BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026	GL
13/04	BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer	AQ
11/04	BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer	GL
26/03	EU General Court: Technical Vaccine Data Does Not Have To Be Disclosed On Request	AQ
24/03	BioNTech : Nachhaltigkeitsbericht 2025 (716624)	PU
24/03	BioNTech : Nachhaltigkeitsbericht 2025	PU